Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2025-01-16
Target enrollment:
Participant gender:
Summary
This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC)
population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy
in the second line or third line setting (Stage 1) and then to expand the group(s) to further
evaluate efficacy in the selected population(s) (Stage 2).